Clinicopathological characteristics and prognosis of adult ovarian granulosa cell tumor: a single-institution experience in China

Dan Wang
Yang Xiang
Ming Wu
Keng Shen
Jiaxin Yang
Huifang Huang
Tong Ren

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China

Objectives: We aimed to demonstrate the clinical characteristics and risk factors associated with recurrence of adult granulosa cell tumor (AGCT), as well as the pregnancy and long-term outcomes among patients in a single institution in China.

Patients and methods: We reviewed 141 patients with AGCT in Peking Union Medical College Hospital between January 1983 and September 2015.

Results: The mean patient age was 45.1 years (16–78 years), and the mean tumor size was 8.8 cm (1–40 cm). The most common symptom was irregular menstruation (31.9%, n=45). The disease distribution was stage I in 136 patients, stage II in three patients, and stage III in two patients. Eighty-seven patients (61.7%) underwent radical surgery, while 54 (38.3%) underwent fertility-sparing surgery, of whom five subsequently had a total of five pregnancies. Fifty-two patients underwent pelvic and/or para-aortic lymphadenectomy, and none of them showed lymph node metastasis. The median follow-up period was 72.7 months (8.9–344 months). Twenty-six patients (18.4%) developed recurrence during the study period, with a median time to recurrence of 68 months (7–312 months). Initial stage (stage IC vs IA) and nonstaging surgery were independent risk factors for recurrence in both univariate and multivariate analyses for stage I AGCT patients.

Conclusion: Tumor stage is an independent risk factor for recurrence in patients with AGCT. Staging surgery is recommended for patients with AGCT, though lymphadenectomy may be omitted. Complete tumor resection is important for patient survival in patients with AGCT recurrence. Long-term follow-up is required, even in early-stage AGCT patients.

Keywords: granulosa cell tumor, ovary, recurrence, pregnancy

Background

Ovarian granulosa cell tumor (GCT) is a rare ovarian neoplasm derived from ovarian sex-cord stromal cells in the ovaries. GCT comprises two kinds of histology: adult granulosa cell tumor (AGCT) and juvenile granulosa cell tumor, of which AGCT accounts for >95% of GCTs and 2%–5% of all ovarian malignancies. Its clinical characteristics include an indolent clinical course and later recurrence, with a better prognosis compared with ovarian epithelial cancers.

Complete tumor resection consisting of bilateral adnexectomy and hysterectomy is the standard treatment for AGCT, with adjuvant chemotherapy recommended in patients with advanced stage or stage I disease with high-risk factors (tumor rupture, high mitotic index). Fertility-sparing surgery with complete staging is recommended for young patients wishing to maintain fertility. However, experience and evidence for the optimal treatment of AGCT are limited. The rarity of AGCT means that the
incidence of lymph node metastasis is not well known and the need for lymphadenectomy is controversial. A few previous studies have considered factors associated with AGCT recurrence, such as International Federation of Gynecology and Obstetrics (FIGO) stage, tumor rupture, tumor diameter, age, menopause, staging surgery, adjuvant chemotherapy, nuclear atypia, and mitotic rate.1–3 The purpose of the present study was to analyze the clinical characteristics and risk factors for recurrence of AGCT based on the long-term outcomes in a large series of patients treated at a single institution in People’s Republic of China. In addition, we discuss the need for lymphadenectomy and the role of fertility-sparing surgery in AGCT in light of the previous studies.

Patients and methods
The study has been approved by the ethics committee of Peking Union Medical College Hospital and is in accordance with the Helsinki Declaration of 1975. Informed written consent from each patient was obtained. Medical records of all patients diagnosed with AGCT of the ovary in Peking Union Medical College Hospital from January 1983 to September 2015 were reviewed. Patients with juvenile GCT were excluded. The patients’ medical records were reviewed and the following information was collected: age, menopause status, tumor diameter, serum CA125 before surgery, chief complaint, FIGO stage, type of surgery, adjuvant therapy, relapse characteristics and relapse treatment, and follow-up information. Follow-up information was obtained from outpatient files or by telephone interviews with the patients or their relatives.

Fertility-sparing surgery was defined as preservation of the uterus and at least one ovary. Total abdominal hysterectomy and bilateral salpingo-oophorectomy were classified as radical surgery. Staging surgery included peritoneal washing, peritoneal biopsy, omentectomy, pelvic and/or para-aortic lymphadenectomy, and appendectomy as optional procedures according to the surgeon’s experience and the intraoperative findings.

Patients were staged according to the FIGO staging system in 2009. Patients with stage II–IV or presence of high-risk factors were given chemotherapy after surgery.

Patients were classified into a recurrence group and a non-recurrence group. Disease-free survival was defined as the time from initial surgery to the first recurrence or censor date.

Statistical analysis
Statistical analysis was performed using SPSS version 15 (SPSS, Inc., Chicago, IL, USA). Recurrence curves were calculated using the Kaplan–Meier method and compared with log-rank tests. Two-sided p-values were considered statistically significant at p<0.05. Multivariate analysis was conducted using a Cox regression model to identify independent factors associated with recurrence. Variables with p<0.05 in univariate analysis were selected for multivariate analysis.

Results
A total of 141 patients underwent surgical treatment for AGCT in Peking Union Medical College Hospital during the study period. The mean age of the patients was 45.1 years (16–78 years), and 46 patients (32.6%) were postmenopausal. The mean tumor size was 8.8 cm (1–40 cm). The most common symptoms included irregular menstruation (31.9%, n=25), postmenstrual bleeding (17.7%, n=25), and abdominal pain (16.3%, n=23). Preoperative serum CA125 levels were available for 98 patients and were elevated in 17 patients (17.3%). The patient characteristics are listed in Table 1.

Most patients had stage I disease (96.4%, n=136), three stage II, and two stage III. All patients underwent surgery, including fertility-sparing surgery in 54 (38.3%) and radical surgery in 87 (61.7%). Fifty-two patients underwent pelvic and/or para-aortic lymphadenectomy, but none showed lymph node metastasis. The surgical pathological features are given in Table 2.

Fifty-six patients (39.7%) received adjuvant chemotherapy after surgery, including bleomycin, etoposide, and cisplatin in 21 patients; cisplatin, vincristine, and bleomycin in nine; cisplatin and cyclophosphamide in nine; paclitaxel

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
</tr>
<tr>
<td>≥50</td>
<td>95 (67.4)</td>
</tr>
<tr>
<td>&gt;50</td>
<td>46 (32.6)</td>
</tr>
<tr>
<td><strong>Tumor size (cm)</strong></td>
<td></td>
</tr>
<tr>
<td>≤10</td>
<td>114 (80.9)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>27 (19.1)</td>
</tr>
<tr>
<td><strong>Menopause</strong></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>95 (67.4)</td>
</tr>
<tr>
<td>Yes</td>
<td>46 (32.6)</td>
</tr>
<tr>
<td><strong>Initial symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>Irregular menstruation</td>
<td>29 (20.6)</td>
</tr>
<tr>
<td>Postmenopausal bleeding</td>
<td>25 (17.7)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>23 (16.3)</td>
</tr>
<tr>
<td><strong>Serum CA125</strong></td>
<td></td>
</tr>
<tr>
<td>Elevated</td>
<td>17 (12.1)</td>
</tr>
<tr>
<td>Normal</td>
<td>81 (57.4)</td>
</tr>
<tr>
<td>Not measured</td>
<td>43 (30.5)</td>
</tr>
</tbody>
</table>

Abbreviation: AGCT, adult granulosa cell tumor.
Table 2 Surgical pathological features of patients with AGCT

<table>
<thead>
<tr>
<th>FIGO stage</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA</td>
<td>71 (50.4)</td>
</tr>
<tr>
<td>Stage IC</td>
<td>65 (46.1)</td>
</tr>
<tr>
<td>Stage II</td>
<td>3 (2.1)</td>
</tr>
<tr>
<td>Stage III</td>
<td>2 (1.4)</td>
</tr>
</tbody>
</table>

Surgical procedure

- Fertility surgery
  - Cystectomy: 5 (3.5)
  - USO: 40 (28.4)
  - USO + staging operation: 9 (6.4)

- Radical surgery
  - H + USO: 37 (26.2)
  - Staging operation: 50 (35.5)

- Staging operation
  - Yes: 59 (41.8)
  - No: 82 (58.2)

- Adjuvant therapy
  - Surgery only: 85 (60.3)
  - Surgery + chemotherapy: 56 (39.7)

- Lymphadenectomy
  - Not performed: 89 (63.1)
  - Performed: 52 (36.9)

Endometrial pathology

- Normal: 56 (39.7)
- Endometrial polyp: 10 (7.1)
- Simple hyperplasia: 10 (7.1)
- Complex hyperplasia without atypia: 3 (2.1)
- Complex hyperplasia with atypia: 3 (2.1)
- Endometrial cancer: 2 (1.4)
- Not measured: 57 (40.4)

First operation at clinical setting

- Outer: 42 (29.8)
- Our clinical: 99 (70.2)

Surgical approach

- Laparoscopy: 54 (38.3)
- Laparotomy: 87 (61.7)

Abbreviations: AGCT, adult granulose cell tumor; FIGO, International Federation of Gynecology and Obstetrics; H + BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy.

The mean age of the patients with recurrence was 40.2 years (27–58 years). The mean time from initial surgery to relapse was 68 months (7–312 months), including 12 patients (46.2%) who suffered recurrences >5 years after their initial diagnosis.

The most common location for recurrence was the pelvic cavity (69.2%, n=18). Fourteen patients suffered one recurrence and 12 patients suffered more than one recurrence, with a maximum of seven recurrences. The longest period from initial diagnosis to recurrence was 26 years.

Treatments for recurrence included surgery alone in five patients, surgery and chemotherapy in 18, surgery and chemoradiation in two, and surgery and radiofrequency ablation in one patient.

Sixteen patients were alive without evidence of disease at the last follow-up, four were alive with disease, two had died as a result of recurrence, three were lost to follow-up, and one patient was receiving therapy.

More than 95% of the patients had stage I disease, and we therefore defined relapse factors for stage I disease. The clinical-pathological factors associated with disease-free survival in 136 patients with stage I AGCT are shown in Table 3. In univariate analysis, recurrence was associated with stage IC and nonstaging surgery (p=0.01, 0.041) (Figure 1A and B), while multivariate analysis also identified stage IC and nonstaging surgery as independent risk factors for recurrence (hazard ratio =3.839, 95% confidence interval =1.430–10.309, hazard ratio =2.673, 95% confidence interval =1.092–6.543).

**Discussion**

We investigated the prognostic significance of risk factors including age, menopausal status, tumor size, surgical method, FIGO stage, and adjuvant chemotherapy for recurrence in patients with AGCT. Both univariate and multivariate analyses identified FIGO stage and surgical method as significant prognostic factors.

FIGO stage is the most widely accepted risk factor for recurrence in patients with AGCT, and several studies have shown correlations between higher disease stage and increased recurrence. The 5-year survival was reported to be 75%–95% in patients with early-stage disease, and this fell to 25%–50% in patients with advanced-stage disease. In the present study, >95% of patients presented with stage I disease, and we therefore analyzed the risk factors for recurrence in stage I disease. Our results also identified initial FIGO stage at diagnosis as an independent risk factor for recurrence.
Complete staging surgery is recommended for patients with early-stage AGCT, and our results also suggested that staging surgery was beneficial in patients with early-stage AGCT. The recurrence rate was lower in patients with staging surgery compared with those without (12.5% vs 22.5%).

<table>
<thead>
<tr>
<th>Factors</th>
<th>Recurrence rate (%)</th>
<th>Univariate HR (95% CI) p-value</th>
<th>Multivariate HR (95% CI) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 50</td>
<td>22.0 (20/91)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>&gt; 50</td>
<td>11.1 (5/45)</td>
<td>0.526 (0.196–1.412)</td>
<td>0.169</td>
</tr>
<tr>
<td>Menopause</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>11.1 (5/45)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>22.0 (20/91)</td>
<td>2.000 (0.745–5.370)</td>
<td>0.234</td>
</tr>
<tr>
<td>Size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 10</td>
<td>20.5 (23/112)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>&gt; 10</td>
<td>8.3 (2/24)</td>
<td>0.415 (0.097–1.766)</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staging</td>
<td>12.5 (7/56)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Unstaged</td>
<td>22.5 (18/80)</td>
<td>2.544 (1.038–6.234)</td>
<td>0.041</td>
</tr>
<tr>
<td>FIGO stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>7.0 (5/71)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>IC</td>
<td>26.7 (20/65)</td>
<td>3.689 (1.375–9.894)</td>
<td>0.01</td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>17.0 (9/53)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>19.3 (16/83)</td>
<td>0.651 (0.280–1.514)</td>
<td>0.319</td>
</tr>
</tbody>
</table>

Abbreviations: AGCT, adult granulose cell tumor; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

Figure 1 Disease-free survival in stage I AGCT patients according to FIGO stage (A) and surgical method (B).

Abbreviations: AGCT, adult granulose cell tumor; FIGO, International Federation of Gynecology and Obstetrics.
those of the previous studies suggested that recurrence was
common in patients with fertility-sparing surgery, and close
monitoring is therefore needed in these patients. Furthermore,
hysterectomy and salpingo-oophorectomy are strongly recom-

mmed after completion of family planning.

5.26% in patients receiving radical surgery. These findings
suggest that the incidence of lymph node metastasis was only
3.9% (Table 5). In accord with previous reports, we found no cases
of lymph node metastasis among 52 patients with nodal

tissue evaluation. Karalok et al reported the highest rate
of lymph node dissection in patients with AGCT to date,
and showed that among 121 of 158 (76.6%) patients with
systematic lymph node dissection, only three had lymph node
metastasis. In addition, lymphadenectomy was not associated
with recurrence. These findings suggest that the incidence of
lymph node metastasis is extremely low in AGCT at primary
surgery, and lymphadenectomy may thus be omitted during
staging surgery.

The patients may develop hyperplasia or endometrial
cancer as a result of prolonged exposure to high levels of
estradiol secreted by the GCT, with reported incidences

ear-stage AGCT. Surgeons should also aim to identify
and excise extraovarian disease in patients with presumed
ear-stage disease.6

Surgery is the primary treatment for AGCT. GCT often
affects younger patients, and fertility preservation is thus
an important issue. However, the role of fertility-sparing
surgery remains unclear. Some studies found that fertility-
sparing management was associated with high recurrence
and low survival rates,7,8 while others found no difference in
recurrence rates between conservative and radical surgery
in patients with stage I disease.2,8 In the current analysis,
fertility-sparing surgery seemed to be a risk factor for
recurrence in AGCT (32.6% vs 13.3%); however, further
analysis of the 54 patients who received fertility-sparing
surgery revealed that most recurrences occurred in patients
who did not undergo staging surgery (28.9%, 13/45), while
the recurrence rate in those who did undergo staging was
only 11.1% (1/9). Eighty-three patients underwent radical
surgery, with a recurrence rate of 13.3%. The recurrence
rate of 11.1% in younger patients with fertility-sparing and
staging surgery was thus acceptable compared with that of
13.3% in patients receiving radical surgery. These findings
reinforce the importance of staging surgery in patients who
want to retain fertility.

We also performed a literature search for information on
pregnancy outcomes in patients received fertility-sparing sur-
gery using PubMed, with the keywords: fertility sparing and
pregnancy and granulosa cell tumor and ovary. We identified
four articles that met the inclusion criteria.5,10–12 The cumu-

late data regarding pregnancy outcomes and recurrence
rates in patients with AGCT after fertility-sparing surgery
are summarized in Table 4. A total of 139 of 515 patients
underwent fertility-sparing procedures, with recurrence rates
of 0%–33.3%. Only 14.4% (20/139) of patients had preg-
nancies after fertility-sparing surgery. Both our results and
those of the previous studies suggested that recurrence was

Table 4 Fertility surgery and pregnancy outcome in patients with AGCT

<table>
<thead>
<tr>
<th>Study</th>
<th>Total number</th>
<th>Fertility sparing</th>
<th>Type of surgery</th>
<th>Recurrence rate</th>
<th>Postoperative pregnancy, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>et al,2 1994</td>
<td>18</td>
<td>6</td>
<td>USO: 6</td>
<td>33.3 (2/6)</td>
<td>50 (3/6)</td>
</tr>
<tr>
<td>et al,10 2009</td>
<td>80</td>
<td>8</td>
<td>USO + staging surgery: 8</td>
<td>0 (0/8)</td>
<td>25 (3/6)</td>
</tr>
<tr>
<td>Lee et al,13 2011</td>
<td>113</td>
<td>36</td>
<td>Cystectomy: 3</td>
<td>NA</td>
<td>22.2 (8/36)</td>
</tr>
<tr>
<td>Lauszus et al,12 2014</td>
<td>163</td>
<td>35</td>
<td>USO: 35</td>
<td>25.7 (9/35)</td>
<td>5.7 (2/35)</td>
</tr>
<tr>
<td>Present study</td>
<td>141</td>
<td>54</td>
<td>Cystectomy: 5</td>
<td>26.0 (14/54)</td>
<td>9.3 (5/54)</td>
</tr>
<tr>
<td>Total</td>
<td>515</td>
<td>139</td>
<td>Cystectomy: 8</td>
<td>24.3 (25/103)</td>
<td>14.4 (20/139)</td>
</tr>
</tbody>
</table>

Abbreviations: AGCT, adult granulosa cell tumor; USO, unilateral salpingo-oophorectomy; NA, not available.

Table 5 Incidence of nodal involvement in studies reporting more than 50 cases

<table>
<thead>
<tr>
<th>Study</th>
<th>Total cases (years)</th>
<th>Nodal involvement in initial surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ertas et al14</td>
<td>108 (1991–2010)</td>
<td>3/58 (5.1%)</td>
</tr>
<tr>
<td>Mangili et al15</td>
<td>97 (1965–2008)</td>
<td>0/15 (0%)</td>
</tr>
<tr>
<td>Karalok et al16</td>
<td>158 (1988–2013)</td>
<td>3/121 (2.5%)</td>
</tr>
<tr>
<td>Park et al17</td>
<td>93 (1991–2010)</td>
<td>0/25 (0%)</td>
</tr>
<tr>
<td>Abu-Rustum et al19</td>
<td>64 (1971–2005)</td>
<td>0/16 (0%)</td>
</tr>
<tr>
<td>Brown et al20</td>
<td>178 (1985–2005)</td>
<td>0/36 (0%)</td>
</tr>
<tr>
<td>Ayhan et al11</td>
<td>80 (1982–2006)</td>
<td>7/80 (8.8%)</td>
</tr>
<tr>
<td>Present study</td>
<td>141 (1983–2015)</td>
<td>0/52 (0%)</td>
</tr>
<tr>
<td>Total</td>
<td>986</td>
<td>17/435 (3.9%)</td>
</tr>
</tbody>
</table>

Note: Range of years represent study periods.

OncoTargets and Therapy 2018:11
of endometrial hyperplasia and endometrial cancer of 21.5%–71% and 1.3%–13.2%, respectively. Sixteen patients (11.3%) in the current study had endometrial hyperplasia and two had endometrial cancer (1.4%) at diagnosis of GCT, which was similar to previous report. Current guidelines for the treatment of GCT recommend comprehensive staging surgery including total hysterectomy and bilateral salpingooophorectomy in postmenopausal/postmenstrual women with AGCT. However, conservative surgery is always recommended in younger patients with a wish to maintain fertility if the tumor is confined to one ovary and the endometrium is normal. van Meurs et al studied endometrial abnormalities in 1,031 patients with GCT during long-term follow-up in a population-based cohort study. Among 490 patients who did not undergo hysterectomy at the time of GCT diagnosis, eight patients (1.6%) developed hyperplasia and two (0.4%) developed endometrial cancer. They concluded that the development of endometrial abnormalities after surgical removal of GCT was extremely rare and lower than the risk of endometrial cancer in the normal population. Furthermore, the endometrial abnormalities were accompanied with recurrence of GCT in 8 of the 10 patients. In our study, 54 patients underwent fertility-sparing surgery and no endometrial abnormalities were observed during follow-up. Fourteen of these patients suffered recurrence, but none developed endometrial lesions. This suggests that spontaneous regression may occur following the discontinuation of estrogen exposure by removal of the GCT. In addition, most patients (90%) with endometrial hyperplasia or cancer were above 40 years old, consistent with a previous study which reported that endometrial pathology was rarely observed in GCT patients under the age of 40 years. Overall, these findings support the safety of conservative surgery in young patients wishing to retain fertility. However, given the common coexistence of endometrial abnormalities, it is important to evaluate the endometrium using ultrasound or curettage when considering conservative surgery in young patients.

In our study, 18.4% of patients with stage I disease had recurrence, with a mean time from initial surgery to relapse of 68 months (7–312 months). AGCT is characterized by slow, indolent growth with later recurrence. The longest disease-free interval in the current study was 26 years, while the longest reported interval between initial diagnosis and recurrence was 37 years. Moreover, almost half of our patients (46.2%, 12/26) had recurrence after more than 5 years. These findings highlight the importance of long-term follow-up of patients with AGCT, even those with early-stage disease.

The pelvis has been reported as the most common site of recurrence. The same result was seen in our study, the pelvis being the most common site (69.2%, 18/26), followed by the abdomen (38.5%, 10/26), lung (7.7%, 2/26), and retroperitoneum (7.7%, 2/26). There is currently no standard management for relapsed GCT, and multiple approaches such as surgery, chemotherapy, radiotherapy, and hormone therapies have been reported. All patients with recurrence in the current study received surgery, with or without other modalities: five patients underwent surgery alone, 18 underwent debulking surgery and chemotherapy, two received surgery and radiotherapy, and one received surgery and radiofrequency ablation. Mangili et al suggested that optimal debulking surgery was the cornerstone treatment for relapse of GCT. However, the absence of residual disease remained a prognostic factor, even at recurrence, and the 5-year overall survival rates from first recurrence were 55.6% and 87.4% for patients with or without residual tumor at subsequent debulking surgery, respectively. Karalok et al reported on 16 patients with relapsed AGCT and showed that maximal debulking could be achieved in all patients with unifocal recurrence, compared with only three patients (37%) with multifocal recurrence. They also found that multifocal recurrence and presence of disease were associated with poorer progression-free survival and overall survival, and concluded that maximum surgical effort is warranted for recurrent AGCT of the ovary. Chua et al demonstrated the feasibility and safety of peritoneectomy to achieve maximal cytoreduction in patients with recurrent AGCT. In the present study, all patients underwent surgical debulking using multiple surgical approaches, such as extensive peritoneectomy, diaphragmatic resection, and partial hepatectomy to achieve optimal cytoreduction. Sixteen patients remained alive without disease at the end of the follow-up period, four were alive with disease, two had died of disease, three were lost to follow-up, and one was undergoing treatment. The outcome of patients with relapsed AGCT thus seems acceptable, compared to that of ovarian epithelial cancer. Complete tumor resection appears to provide the best chance of patient survival, and surgeons should aim to excise recurrent foci.

The present study had some limitations. First, the rarity of GCT makes it hard to carry out well-designed studies. Second, this was a retrospective study conducted over a long period, and some information was missing as a result of loss of follow-up, while changes in practice patterns over the course of the study may also have affected the outcome. However, the present study also had several strengths. Notably, it was the first single-center study conducted in China, with a long follow-up period (median follow-up: 72.7 months). Furthermore, the number of cases (n=141) represents one of the largest reported studies of patients with...
GCT, and all patients were handled by experienced gynecologic oncologists. Finally, in addition to AGCT outcomes, we also analyzed pregnancy results, which have rarely been reported in previous studies.

**Conclusion**

Most cases of AGCT are diagnosed at an early stage, but complete staging surgery is recommended for all patients with AGCT. Lymph node metastasis is rare among AGCT, and lymphadenectomy can thus be omitted from staging surgery. Unilateral salpingo-oophorectomy including staging surgery is the optimal treatment in younger patients who wish to retain fertility, with no compromise in terms of survival. In addition, it is important to carry out ultrasound or curettage to evaluate endometrial abnormalities in young patients considering conservative surgery. Maximal surgical resection is important for survival in patients with AGCT relapse, and lifetime follow-up is required, even in patients with early-stage disease, because of the risk of later recurrence.

**Acknowledgment**

We thank Susan Furness, PhD, from Liwen Bianji, Edanz Group, People’s Republic of China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

**Author contributions**

All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


